Tai Sun Park1, Hye-Ryoun Kim2, Jae Soo Koh3, Seung Hun Jang4, Yong Il Hwang4, Ho Il Yoon5, Jin-Haeng Chung6, Cheol Hyeon Kim2, Sung-Soo Kim7, Woo Sung Kim1, Jungmin Jo8, Jae Cheol Lee8, Chang-Min Choi9. 1. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 2. Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Republic of Korea. 3. Department of Pathology, Korea Cancer Center Hospital, Seoul, Republic of Korea. 4. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Sacred Heart Hospital, Anyang, Republic of Korea. 5. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 6. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 7. Department of Healthcare Management, Cheongju University, Cheongju, Republic of Korea. 8. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 9. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: ccm@amc.seoul.kr.
Abstract
OBJECTIVES: Although adjuvant platinum-based chemotherapy improves survival in completely resected non-small cell lung cancer (NSCLC), its effect is limited. We evaluated whether the expression of heat shock protein 70 (Hsp70) is associated with clinical outcomes in patients with completely resected NSCLC who were treated with or without adjuvant platinum-based chemotherapy. PATIENTS AND METHODS: Patients who underwent curative resection for NSCLC and diagnosed as stage IIA through IIIA were included. Immunohistochemical staining for Hsp70 was performed on surgical specimens and survival rates were compared by Hsp70 expression and adjuvant platinum-based chemotherapy. RESULTS: Of 327 enrolled patients, Hsp70 expression was positive in 220 (67.3%). For patients who did not receive adjuvant chemotherapy, Hsp70 expression did not significantly affect survival. However, for patients who received adjuvant chemotherapy, those with Hsp70-positive tumors had a longer disease-free survival outcome than cases with Hsp70-negative tumors (not reached vs. 27.3 months; P=0.002), although there was no significant difference in overall survival (97.0 vs. 58.9 months, P=0.080). In the adjuvant chemotherapy group, multivariate modeling showed that patients with Hsp70-postitive tumors had a lower risk of recurrence and death after adjusting for age, sex, performance status, pathologic stage, and histological type (disease-free survival: adjusted hazard ratio, 0.537; 95% CI, 0.362-0.796; P=0.002; overall survival: adjusted hazard ratio, 0.663; 95% CI, 0.419-1.051; P=0.080). CONCLUSION: Hsp70 is a positive predictive factor in completely resected NSCLC with received platinum-based adjuvant chemotherapy.
OBJECTIVES: Although adjuvant platinum-based chemotherapy improves survival in completely resected non-small cell lung cancer (NSCLC), its effect is limited. We evaluated whether the expression of heat shock protein 70 (Hsp70) is associated with clinical outcomes in patients with completely resected NSCLC who were treated with or without adjuvant platinum-based chemotherapy. PATIENTS AND METHODS: Patients who underwent curative resection for NSCLC and diagnosed as stage IIA through IIIA were included. Immunohistochemical staining for Hsp70 was performed on surgical specimens and survival rates were compared by Hsp70 expression and adjuvant platinum-based chemotherapy. RESULTS: Of 327 enrolled patients, Hsp70 expression was positive in 220 (67.3%). For patients who did not receive adjuvant chemotherapy, Hsp70 expression did not significantly affect survival. However, for patients who received adjuvant chemotherapy, those with Hsp70-positive tumors had a longer disease-free survival outcome than cases with Hsp70-negative tumors (not reached vs. 27.3 months; P=0.002), although there was no significant difference in overall survival (97.0 vs. 58.9 months, P=0.080). In the adjuvant chemotherapy group, multivariate modeling showed that patients with Hsp70-postitive tumors had a lower risk of recurrence and death after adjusting for age, sex, performance status, pathologic stage, and histological type (disease-free survival: adjusted hazard ratio, 0.537; 95% CI, 0.362-0.796; P=0.002; overall survival: adjusted hazard ratio, 0.663; 95% CI, 0.419-1.051; P=0.080). CONCLUSION:Hsp70 is a positive predictive factor in completely resected NSCLC with received platinum-based adjuvant chemotherapy.
Authors: Friederike Lämmer; Claire Delbridge; Silvia Würstle; Frauke Neff; Bernhard Meyer; Jürgen Schlegel; Kerstin A Kessel; Thomas E Schmid; Daniela Schilling; Stephanie E Combs Journal: PLoS One Date: 2019-08-20 Impact factor: 3.240
Authors: Richard Smith; Jiaxi Wang; Colin Seymour; Cristian Fernandez-Palomo; Jennifer Fazzari; Elisabeth Schültke; Elke Bräuer-Krisch; Jean Laissue; Christian Schroll; Carmel Mothersill Journal: Dose Response Date: 2018-01-22 Impact factor: 2.658